ESTEVE ANNOUNCES THE APPOINTMENT OF ITS FOURTH INDEPENDENT DIRECTOR, JACQUES TAPIERO
A few months ago, ESTEVE began an important reorganization of its governing bodies with the appointment of three independent members to the Board of Directors, the departure of a few proprietary directors, and the restructure of all its commissions. As anticipated, the Company today confirmed the appointment of a fourth independent director with a proven track record of success.
Jacques Tapiero has developed most of his professional career at the pharmaceutical company Eli Lilly. For more than 30 years at this Indianapolis-based American multinational corporation, Jacques Tapiero has held different responsible positions in several countries. Before leaving the company he was Senior Vice President, a member of the Executive Committee, and President of Emerging Markets. In this latter position his primary focus included the development of Lilly in the markets with highest growth potential: China, Russia, Brazil, Mexico, South Korea, and Turkey. Mr. Tapiero was responsible for the management of a turnover of more than 2.5 billion dollars in more than 70 countries.
Presently, Jacques Tapiero is a member of the Board of Directors at McCormick & Company, a global leader in flavor. He is also a senior consultant at McKinsey & Company, an advisor at the GLG Institute, and a member of the executive directorate at the prestigious Thunderbird School of Global Management.
Mr. Tapiero was born in Morocco and he is a Swiss and a North American citizen. He graduated with a degree in Business Administration and Management at the École Supérieure de Commerce of Clermont Ferrand (France). In 1982 he received his MBA from the American Graduate School of International Management, Glendale, Arizona (USA).
ESTEVE's Board of Directors is presided over by Joan Esteve and the Group's executive management structure is led by its CEO Albert Esteve.
Members of the Board of Directors in January 2017
Joan Esteve, President
Albert Esteve, Chief Executive Officer
Antoni Esteve (Proprietary Director)
Jordi Esteve (Proprietary Director)
Silvia Gil-Vernet (Proprietary Director)
Joaquin Monleón (Proprietary Director)
Santiago Descarrega (Proprietary Director)
Jacques Tapiero (Independent Director)
Jesús Caínzos (Independent Director)
Alessandro Banchi (Independent Director)
Julio Rodríguez (Independent Director)
Jordi Faus (Secretary, not a Director)
Daniel Girona (Vice Secretary, not a Director)
THE PROGRAM ’PLAN PROFARMA’ HAS ONCE AGAIN QUALIFIED ESTEVE’S R&D&I AS ’’EXCELLENT’’
Once again, ESTEVE's research activity has received the qualification ''Excellent'' in the Program 'Plan Profarma' (Program for Fostering Scientific Research, Technological Development and Innovation ...read more
PENSA PHARMA HAS BEEN AWARDED A PRIZE FOR ITS BEST DEVELOPMENT AND COMMERCIALIZATION OF GENERIC MEDICINES
Pensa Pharma (PENSA), a company of the ESTEVE Group specialized in generic medicines, has been awarded a prize at the II edition of La Razón Comunidad Valenciana Awards. Specifically, PENSA has receiv...read more
ESTEVE APPOINTS THOMAS B. RIISAGER AS CHIEF CORPORATE STRATEGY & BUSINESS DEVELOPMENT OFFICER
ESTEVE has announced today the appointment of Thomas B Riisager as Chief Corporate Strategy & Business Development Officer, to be heading Corporate Strategy & Business Development for the pharmaceutic...read more